

Title (en)
HIV IMMUNOGENIC COMPOSITIONS AND METHODS

Title (de)
HIV IMMUNOGENE ZUSAMMENSETZUNGEN UND METHODEN

Title (fr)
COMPOSITIONS ET PROCEDES IMMUNOGENES ANTI-VIH

Publication
EP 1176978 A2 20020206 (EN)

Application
EP 00932163 A 20000505

Priority
• US 0012495 W 20000505
• US 13276299 P 19990506
• US 15066799 P 19990825

Abstract (en)
[origin: WO0067787A2] The invention provides immunogenic compositions which enhance beta -chemokine levels in a mammal. The immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided are kits, the components of which, when combined, produce the immunogenic compositions of the invention. The invention also provides methods of making the immunogenic compositions, by combining an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The invention further provides a method of immunizing a mammal, by enhancing beta -chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. Also provided is a method of inhibiting AIDS, by enhancing beta -chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant.
[origin: WO0067787A2] The invention provides immunogenic compositions which enhance beta-chemokine levels in a mammal. The immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided is a method of inhibiting AIDS, by enhancing beta-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant.

IPC 1-7
A61K 39/21; **A61K 39/39**; **A61P 31/18**

IPC 8 full level
A61K 39/21 (2006.01); **A61K 39/39** (2006.01); **A61P 31/18** (2006.01)

CPC (source: EP)
A61K 39/12 (2013.01); **A61K 39/21** (2013.01); **A61K 39/39** (2013.01); **A61P 31/18** (2017.12); **A61K 2039/5252** (2013.01); **A61K 2039/55505** (2013.01); **A61K 2039/55561** (2013.01); **A61K 2039/55566** (2013.01); **A61K 2039/55572** (2013.01); **A61K 2039/57** (2013.01); **C12N 2740/16034** (2013.01)

Citation (search report)
See references of WO 0067787A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0067787 A2 20001116; **WO 0067787 A3 20010426**; AP 1891 A 20080923; AP 2001002300 A0 20011231; AU 4992900 A 20001121; BR 0010323 A 20020108; CA 2372960 A1 20001116; CA 2372960 C 20060328; CR 6491 A 20050531; EP 1176978 A2 20020206; OA 11937 A 20060412

DOCDB simple family (application)
US 0012495 W 20000505; AP 2001002300 A 20000505; AU 4992900 A 20000505; BR 0010323 A 20000505; CA 2372960 A 20000505; CR 6491 A 20011025; EP 00932163 A 20000505; OA 1200100291 A 20000505